GenAssist Ltd (GenAssist), a pioneering gene-editing biotechnology company for genome medicines, announce that two of our posters for presentation will be released at American Society of Gene and Cell Therapy’s (ASGCT) Breakthroughs in Muscular Dystrophy, which will take place November 19-20, 2024, at The Westin Michigan Avenue Chicago, IL.
Several latest advancements in first DMD base editing drug and PKPD data will be featured by poster presentations from GenAssist at ASGCT Breakthroughs, which covered a range of cutting-edge research topics:
We are eager to showcase our innovative work at this prestigious event.
Stay tuned for updates.
Breakthroughs in Muscular Dystrophy is an international conference by ASGCT and the Muscular Dystrophy Association Annual Meeting, dedicated to sharing the latest groundbreaking advancements in gene and cell therapies for muscular dystrophy worldwide. Industry experts from DMD, including SAREPTA and Catalyst pharmaceutical, will also be attending this prestigious event.
More information is available on the ASGCT Breakthroughs website (https://www.asgct.org/events/breakthroughs-in-muscular-dystrophy).
